Patients with PPP2R1A-mutated endometrial cancer showed significantly improved survival on lenvatinib-pembrolizumab combination therapy compared to those with wild-type PPP2R1A.

Scientists at UCSD have identified ADAR1p150 as a key target in cancer progression, discovering its role in activating cancer stem cells and enabling immune system evasion across 20 different cancer types.

A comprehensive study of 44,992 individuals reveals that fasting plasma glucose levels, even within normal range, significantly influence diabetes risk, with a 12.8% cumulative 10-year incidence rate.

The BRIDGE clinical trial demonstrated that an AI-enabled chatbot was equally effective as standard-of-care approaches in helping eligible individuals complete cancer genetic testing, with completion rates of 12.3% versus 13.6% respectively.

A systematic literature review presented at ASH 2024 demonstrates that clinical trials significantly underestimate the health-related quality of life burden in relapsed/refractory multiple myeloma patients compared to real-world settings.

Dr. Joshua Sabari from NYU Langone Health highlights the complexity of HER2 alterations in NSCLC, with exon 20 insertions being the most common and therapeutically relevant subtype.

The European Medicines Agency's CHMP has recommended approval of ENHERTU® for patients with HER2 low or ultralow metastatic breast cancer who have received prior endocrine therapy.

Seismic Therapeutic's S-8484, an engineered IgE protease, demonstrates rapid and sustained degradation of IgE in both plasma and B cell receptors, showing potential for treating allergic diseases.

Phase 2 trial results demonstrate CAN-2409 significantly extended median overall survival to 31.4 months compared to 12.5 months in control group for borderline resectable pancreatic cancer patients.

Light AI's novel algorithm demonstrates 96.57% accuracy in distinguishing between viral and bacterial pharyngitis through smartphone image analysis, with a 100% negative predictive value for Strep A detection.

CARsgen Therapeutics has partnered with Zhuhai SB Xinchuang, securing RMB 80 million investment for its subsidiary UCARsgen to develop allogeneic CAR-T cell therapies in mainland China.

BasgenBio secures a 1 billion won ($684,090) deal with Novartis to implement AI-driven digital twin technology for predicting side effects in breast cancer patients.

HTD1801, a plant-derived berberine medication, demonstrated significant blood glucose control in type 2 diabetes patients, with the highest dose reducing HbA1c by 0.7% over 12 weeks.

Distinguished neurologist Professor Patrick Vermersch identifies mast and microglia cells as key catalysts in neurodegenerative diseases, highlighting their role in conditions like multiple sclerosis and Alzheimer's disease.

New data from a 2,854-patient registry study shows Blue Light Cystoscopy detected additional malignant lesions in 7% of cases that were missed by standard white light examination.

New research reveals Breast Cancer Index (BCI) can identify approximately 20% of postmenopausal women with HR-positive, node-negative breast cancer who have minimal recurrence risk, potentially allowing for shorter endocrine therapy.

A large-scale Phase 3 trial in Burkina Faso reveals that repeated high-dose ivermectin mass drug administration did not significantly reduce malaria incidence when combined with seasonal malaria chemoprevention.

HUTCHMED has completed enrollment of 87 patients in a Phase II registration trial evaluating fanregratinib for intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement.

Final analysis of CALYPSO trial demonstrates significant efficacy with savolitinib-durvalumab combination, showing 53% response rate in MET-driven papillary renal cancer patients.

A groundbreaking Phase I/II clinical trial demonstrates 93% manufacturing success rate for Cultivated Autologous Limbal Epithelial Cell (CALEC) transplantation, offering new hope for limbal stem cell deficiency patients.